BRIEF-<a href="https://laohu8.com/S/RXRX">Recursion</a>'s Tupelo Trial Phase 1B/2 Results Show Polyp Burden Reductions In FAP At 25 WeeksDec 8 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O:
RECURSION: REC-4881 TUPELO TRIAL PHASE 1B/2 RESULTS SHOW RAPID & DURABLE REDUCTIONS IN POLYP BURDEN IN FAMILIAL ADENOMATOUS POLYPOSIS AT 25 WEEKS
RECURSION: 82% OF EVALUABLE PATIENTS OF REC-4881 TUPELO TRIAL MAINTAINED REDUCTIONS AT WEEK 25, WITH 53% MEDIAN DECREASE FROM BASELINE
RECURSION: REC-4881 HAS SAFETY PROFILE CONSISTENT WITH MEK1/2 INHIBITION
RECURSION: TO ENGAGE FDA IN 1H26 TO DEFINE POTENTIAL REGISTRATION PATHWAY FOR REC-4881
RECURSION: TO EXPAND POPULATION FROM ≥55 TO ≥18 YEARS OLD & FURTHER OPTIMIZE DOSING SCHEDULE FOR REC-4881
Further company coverage: RXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments